BC cells overexpressing SOX2 are highly proliferative, invasive, and tumorigenic 15, 25 and showed frequent resistance to chemotherapeutic drugs in clinical settings, resulting in poor prognosis in patients with BC 26. This evidence concerns the gene SOX2 and breast cancer.